Fenozolone
Fenozolone (Ordinator) is an oxazolone CNS stimulant related to pemoline, marketed historically in parts of Europe for fatigue, attention and mild depression. It shares the oxazolidinone/oxazolone stimulant lineage and is now largely obsolete with sparse modern data.
01 Overview
Fenozolone is chemically and pharmacologically similar to pemoline, producing gradual, long-acting stimulation with a relatively mild sympathomimetic profile. It was used for asthenia, attention problems and lethargic depression.
It never achieved wide international use and has effectively fallen out of practice. Available pharmacology is older and limited, and it is treated as a controlled/prescription-legacy stimulant where records exist.
02 Mechanism
Oxazolone stimulant acting as an indirect dopaminergic/noradrenergic agent, increasing catecholamine transmission similarly to pemoline.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Historical | 10–20 mg/day | Oral | Historical adult dosing, morning. |
| Historical common | 20–40 mg/day | Oral | Divided doses in older regimens. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Anti-fatigue / alertnessReduced fatigue and improved concentration in historical use. | n/a | Observational | |
| Mood elevationMild mood-lifting effect in asthenic/depressive states. | n/a | Observational |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| InsomniaSleep disturbance from long-acting stimulation. | Mild | Common | Observational | |
| Appetite suppressionReduced appetite. | Mild | Common | Observational | |
| Potential hepatic concernAs a pemoline analogue, idiosyncratic hepatic risk cannot be excluded, though not well documented. | Moderate | Rare | Unconfirmed |